,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000P0BIZ2A3'}, 'Id': 'a0POZ00000P0BIZ2A3', 'Event_Date__c': '2022-03-10', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000DciqQAC'}, 'change': None}]",Mar 2022,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2024', 'fs': 'Jul 2024', 'change': None}, 'Event_Description': {'s': 'Assigned to Ophthalmology Advisory Committee meeting to provide advice on Friday 9 August 2024', 'fs': 'Assigned to Ophthalmology Advisory Committee meeting to provide advice on Friday 9 August 2024', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000P0BIa2AN'}, 'Id': 'a0POZ00000P0BIa2AN', 'Event_Date__c': '2024-07-10', 'Event_Description__c': 'Assigned to Ophthalmology Advisory Committee meeting to provide advice on Friday 9 August 2024', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2024', 'Status_History__c': 'a13OZ00000Cyg8pYAB'}, 'change': None}, {'Summary': {'s': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Ophthalmology Advisory Committee </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">did</strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;""> </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">not recommend </strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">the listing of ziv-aflibercept in place of, or as an alternative to aflibercept (or an aflibercept biosimilar) for currently funded indications based on insufficient evidence that it is therapeutically equivalent.</span></p><p><br></p><p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Committee </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">recommended </strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">that Pharmac should consider the funding of a biosimilar aflibercept either as an alternative to or alongside the currently funded brand if this would allow access to aflibercept to be widened to additional ophthalmology indications.</span></p><p><br></p><p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Committee </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">recommended</strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;""> that access be widened to an anti- vascular endothelial growth factor (VEGF) agent, with a </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">high priority</strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;""> for the second-line treatment of retinal vein occlusion (RVO) within the context of treatment for ophthalmology, subject to Special Authority criteria.</span></p>', 'fs': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Ophthalmology Advisory Committee </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">did</strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;""> </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">not recommend </strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">the listing of ziv-aflibercept in place of, or as an alternative to aflibercept (or an aflibercept biosimilar) for currently funded indications based on insufficient evidence that it is therapeutically equivalent.</span></p><p><br></p><p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Committee </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">recommended </strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">that Pharmac should consider the funding of a biosimilar aflibercept either as an alternative to or alongside the currently funded brand if this would allow access to aflibercept to be widened to additional ophthalmology indications.</span></p><p><br></p><p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Committee </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">recommended</strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;""> that access be widened to an anti- vascular endothelial growth factor (VEGF) agent, with a </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">high priority</strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;""> for the second-line treatment of retinal vein occlusion (RVO) within the context of treatment for ophthalmology, subject to Special Authority criteria.</span></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/2024-08-09-Ophthalmology-Advisory-Committee-record.pdf#page=26"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/2024-08-09-Ophthalmology-Advisory-Committee-record.pdf#page=26"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2024', 'fs': 'Aug 2024', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Ophthalmology Advisory Committee at meeting Friday 9 August 2024.', 'fs': 'Clinical advice received from Ophthalmology Advisory Committee at meeting Friday 9 August 2024.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000P0BIb2AN'}, 'Id': 'a0POZ00000P0BIb2AN', 'Event_Date__c': '2024-08-09', 'Event_Description__c': 'Clinical advice received from Ophthalmology Advisory Committee at meeting Friday 9 August 2024.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/2024-08-09-Ophthalmology-Advisory-Committee-record.pdf#page=26"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'Outcome__c': 'High', 'Summary__c': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Ophthalmology Advisory Committee </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">did</strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;""> </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">not recommend </strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">the listing of ziv-aflibercept in place of, or as an alternative to aflibercept (or an aflibercept biosimilar) for currently funded indications based on insufficient evidence that it is therapeutically equivalent.</span></p><p><br></p><p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Committee </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">recommended </strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">that Pharmac should consider the funding of a biosimilar aflibercept either as an alternative to or alongside the currently funded brand if this would allow access to aflibercept to be widened to additional ophthalmology indications.</span></p><p><br></p><p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Committee </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">recommended</strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;""> that access be widened to an anti- vascular endothelial growth factor (VEGF) agent, with a </span><strong style=""font-family: Arial, sans-serif; font-size: 11pt;"">high priority</strong><span style=""font-family: Arial, sans-serif; font-size: 11pt;""> for the second-line treatment of retinal vein occlusion (RVO) within the context of treatment for ophthalmology, subject to Special Authority criteria.</span></p>', 'Formatted_Date__c': 'Aug 2024', 'Status_History__c': 'a13OZ00000I5b9aYAB'}, 'change': None}]",Jul 2024,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2025', 'fs': 'May 2025', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000P0BIc2AN'}, 'Id': 'a0POZ00000P0BIc2AN', 'Event_Date__c': '2025-05-29', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2025', 'Status_History__c': 'a13OZ00000NyrUGYAZ'}, 'change': None}]",May 2025,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2025', 'fs': 'Aug 2025', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000P0BId2AN'}, 'Id': 'a0POZ00000P0BId2AN', 'Event_Date__c': '2025-08-15', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Aug 2025', 'Status_History__c': 'a13OZ00000RDTBNYA5'}, 'change': None}]",Aug 2025,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
